Stanford University HIV Drug Resistance Database - A curated public database designed to represent, store, and analyze the divergent forms of data underlying HIV drug resistance.

Advisory Committee for the Stanford HIVDB Drug Resistance Interpretation System

Jonathan M. Schapiro, MD received his medical degree from Ben-Gurion University, and his Internship and Internal Medicine training at the Rabin Medical Center in Israel. Subsequently he completed a Fellowship in Infectious Diseases and Geographic Medicine at the Stanford University School of Medicine focusing on antiretroviral drug development at the Stanford Center for AIDS Research.

His research has focused on the causes of antiretroviral drug failure, interventions to optimize clinical care, and new drug development. His interests have included resistance and cross-resistance between drugs, clinical pharmacology, and development of new antiretroviral agents with improved resistance and pharmacological characteristics. His publications have appeared in journals such as Annals of Internal Medicine and The Lancet. He continues his work on the Stanford HIV Drug Resistance Database and the Liverpool HIV Drug Interactions Website.

Dr. Schapiro has served as a member and advisor of numerous US and international HIV expert panels and working groups including the United States Food and Drug Administration (FDA) Antiviral Drugs Advisory Committee, WHO Resistance Network, and the IAS-USA Drug Resistance Group. He currently runs the HIV/AIDS clinic at the National Hemophilia Center in Tel Aviv, and is very active in postgraduate educational programs for HIV treating physicians.
 

Daniel R. Kuritzkes, MD received his BS and MS degrees in Molecular Biophysics and Biochemistry from Yale University, and his MD from Harvard Medical School. He completed his clinical and research training in internal medicine and infectious diseases at Massachusetts General Hospital and was a visiting scientist at the Whitehead Institute for Biomedical Research before joining the faculty at the University of Colorado Health Sciences Center. Dr. Kuritzkes returned to Harvard Medical School in 2002, where he is now the Harriet Ryan Albee Professor of Medicine and Chief, Division of Infectious Diseases at Brigham and Women’s Hospital.

Dr. Kuritzkes has published extensively on antiretroviral therapy and drug resistance in HIV-1 infection. He has chaired several multicenter studies of HIV therapy and previously chaired the AIDS Clinical Trials Group. He has served on numerous NIH committees, including as a member of the NIH Office of AIDS Research Advisory Council. He is a former member of the Department of Health and Human Services panel on guidelines for antiretroviral therapy and a past Chair of the HIV Medicine Association Board of Directors. He has been a member of several editorial boards, and serves as an Associate Editor of the Journal of Infectious Diseases. His research interests focus on HIV therapeutics, antiretroviral drug resistance, and HIV eradication.
 

Michelle Moorhouse, MD graduated from Wits University in South Africa, soon after which she became involved in the management of people living with HIV, and co-founded the first HIV clinical trial center in Port Elizabeth, South Africa. In 2003 Michelle was awarded an Honorary Clinical Fellowship at the Royal Free Hospital in London. She also worked in the pharmaceutical industry, holding senior HIV/virology posts in several large companies.

Michelle is currently the Head of Treatment Strategies at Ezintsha, a subdivision of Wits Reproductive Health and HIV Institute (University of Witwatersrand, Johannesburg), where she is actively engaged in clinical work, research and teaching. Michelle sits on National guideline committees (Adult ART, PrEP, viral hepatitis, cryptococcus, AGYW) to mention a few of her responsibilities. The main thrust of her work currently is in HIV treatment optimisation and she is coinvestigator on the large ADVANCE study. She is a member of the National Third Line ART Committee, as well as the National HIV Drug Resistance Strategy Steering Committee, and WHO HIV Resistance Network. Michelle holds a joint appointment as a researcher in the Faculty of Health Sciences of the University of the Witwatersrand. In 2012, Michelle was elected to the inaugural Board of Directors of the SAHIVCS, and served on the Board until December 2018. She also served as a member of the Editorial Board of HIV Nursing Matters, and Editor-in-Chief of the SA Journal of HIV Medicine until January 2019. She is also an active reviewer for several international journals, and has reviewed abstracts for several international conferences as well as presenting and chairing sessions at HIV conferences.